NYRADA INC-CDI

0.190

0.000

Volume:839.40K

Turnover:161.88K

Market Cap:40.07M

PE:-8.70

High:0.195

Open:0.190

Low:0.190

Close:0.190

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Nyrada Receives Ethics Committee Approval to Modify Phase One Clinical Trial Protocol; Shares Fall 3%

MT Newswires Live

·

04 Jun

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NYR.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NYR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","market":"AU","secType":"STK","nameCN":"NYRADA INC-CDI","latestPrice":0.19,"timestamp":1749190320000,"preClose":0.19,"halted":0,"volume":839396,"delay":0,"nameEN":"NYRADA INC-CDI","floatShares":129248884,"shares":210917037,"eps":-0.021836,"marketStatus":"Closed King Birthday Day","change":0,"latestTime":"06-06 16:12:00 AEST","open":0.19,"high":0.195,"low":0.19,"amount":161883,"amplitude":0.026316,"askPrice":0.19,"askSize":92445,"bidPrice":0.185,"bidSize":210675,"shortable":3,"etf":0,"ttmEps":-0.021836,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.19,"openAndCloseTimeList":[[1749168000000,1749189600000]],"volumeRatio":0.5511266635116628,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","floatShares":129248884,"roa":"-45.16%","roe":"-76.35%","lyrEps":-0.008535,"volumeRatio":0.5511266635116628,"shares":210917037,"dividePrice":0,"high":0.195,"amplitude":0.026316,"preClose":0.19,"low":0.19,"week52Low":0.032,"pbRate":"6.84","psRate":"24.30","week52High":0.195,"institutionHeld":0,"latestPrice":0.19,"committee":0.390044,"eps":-0.021836,"divideRate":0,"volume":839396,"delay":0,"ttmEps":-0.021836,"open":0.19,"prevYearClose":0.094,"prevWeekClose":0.19,"prevMonthClose":0.165,"prevQuarterClose":0.107,"fiveDayClose":0.165,"twentyDayClose":0.105,"sixtyDayClose":0.105},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NYR.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NYR.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540332670","title":"Nyrada Receives Ethics Committee Approval to Modify Phase One Clinical Trial Protocol; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540332670","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540332670?lang=en_us&edition=fundamental","pubTime":"2025-06-04 13:07","pubTimestamp":1749013678,"startTime":"0","endTime":"0","summary":"Nyrada  received human research ethics committee approval to modify its phase one clinical trial protocol, according to a Wednesday Australian bourse filing.The amendments allow for the evaluation of the safety, tolerability, and pharmacokinetics of Xolatryp, a small-molecule cardioprotection and neuroprotection therapy candidate, in healthy volunteers at higher doses and over a longer infusion duration.The phase one trial will consist of six cohorts, and results are expected in the September quarter.The amended protocol will give the firm greater flexibility in designing a phase two trial, including the ability to optimize dosing for the target patient population, per the filing.The firm's shares fell 3% in recent trading on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2537908600","title":"Nyrada Renames Lead Drug Candidate; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537908600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537908600?lang=en_us&edition=fundamental","pubTime":"2025-05-23 11:21","pubTimestamp":1747970481,"startTime":"0","endTime":"0","summary":"Nyrada  renamed its lead drug candidate targeting neuroprotection and cardioprotection to Xolatryp, according to a Friday filing with the Australian bourse.A trademark application for the name has been filed, the filing said.The drug candidate was previously referred to as NYR-BI03, according to the filing.Shares were down 4% in midday trade Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7096","XJO.AU","NYR.AU","XAO.AU"],"gpt_icon":0},{"id":"2537067987","title":"Nyrada's Phase One Drug Trial Clears Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2537067987","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537067987?lang=en_us&edition=fundamental","pubTime":"2025-05-21 10:53","pubTimestamp":1747795993,"startTime":"0","endTime":"0","summary":"Nyrada  said no issues were raised by the safety review committee after assessing phase one clinical trial data of its drug candidate NYR-BI03, developed to reduce brain and heart damage from brain injury and stroke, according to a Wednesday filing with the Australian bourse.The committee assessed cumulative safety and pharmacokinetic data from the first three cohorts of the trial, the filing said.Recruitment for the fourth cohort has been completed, the company added.Final results from the phase one trial are expected in the third quarter of the year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2536679676","title":"Noxopharm Raises AU$2.5 Million Through Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2536679676","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536679676?lang=en_us&edition=fundamental","pubTime":"2025-05-20 14:26","pubTimestamp":1747722400,"startTime":"0","endTime":"0","summary":"Noxopharm  said it has raised nearly AU$2.5 million in non-dilutive funding by selling its entire stake in Biotechnolgy company Nyrada , according to a Tuesday filing with the Australian bourse.The proceeds will be used to launch the upcoming Heracles clinical trial and invest in research and development, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7508","NYR.AU","NOX.AU","BK7067","XAO.AU","BK7096","XJO.AU","BK7501"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NYR.AU\",params:#limit:5,,,undefined,":[{"date":"2023-07-28","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690502400000,"name":null,"time":"","dateTimestamp":1690466400000,"actualEps":null},{"date":"2023-04-29","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1682726400000,"name":null,"time":"","dateTimestamp":1682690400000,"actualEps":null},{"market":"AU","date":"2022-08-29","symbol":"NYR.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1661695200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NYR.AU\",market:\"AU\",,,undefined,":[]}}